Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

EarningsIBTROZIPositive

AI Analysis

Summary

Nuvation Bio reported Q2 2026 financial results with $31.7 million total revenue, including $23.2 million in net product revenue for IBTROZI (taletrectinib), which is the most prescribed ROS1 TKI in both first-line and overall new patient starts in 2026 based on IQVIA data.

Financial Highlights

Revenue

$31.7 million

Importance:5/10

Sentiment:

0.60

earningsQ2 2026 resultsproduct revenueIBTROZImarket leadershipROS1 inhibitor

Related Companies

$NUVB $IQV

Read the original article

Published by PR Newswire Biotech on August 6, 2026 11:30 AM

Read Original